- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma2016 | Faculty of Medicine in Hradec Králové
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR2018 | First Faculty of Medicine
- Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party2018 | Publication without faculty affiliation